This compound is not approved as a drug, diagnostic, or dietary ingredient, and is not manufactured, packaged, or marketed for consumption, self experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.
ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-Cell Tumors [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Acute Gallbladder Disease [see Warnings and Precautions (5.3)] Hypoglycemia [see Warnings and Precautions (5.4)] Acute Kidney Injury due to Volume Depletion [see Warnings and Precautions (5.5)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions (5.8)] Heart Rate Increase [see Warnings and Precautions (5.9)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.10)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.11)] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice
That difference may also influence the prevalence and severity of side effects
Stress management Stress can affect how your digestive system works and may make symptoms like sulfur burps worse
Revista de Nutrio, v
Managing Cold Sores While Taking Mounjaro When to Seek Medical Advice: Cold Sores and Mounjaro Treatment Scientific References Frequently Asked Questions Understanding Mounjaro (Tirzepatide) and Its Mechanism of Action Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
